Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study

Article Gastroenterology & Hepatology

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Corey A. Siegel et al.

GUT (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Michael D. Kappelman et al.

GASTROENTEROLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

Add to Collection

Article Microbiology

Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods

Emma English et al.

Summary: In the early stages of the COVID-19 pandemic, numerous new serology tests were developed without rigorous evaluation, leading to inconsistent results. Robustly evaluated quantitative serology methods are needed, harmonized to a primary reference material for improved clinical decision making.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays

Ahmed Ismail et al.

Summary: Three fully automated anti-SARS-CoV-2 immunoassays were compared for their performance in predicting neutralizing activity. The VITROS (R) and CL-900i (R) assays demonstrated the highest diagnostic sensitivity and correlation with neutralizing activity. ROC curve analysis indicated that the manufacturer's recommended cutoff values are effective in predicting the presence of neutralizing antibodies.

FRONTIERS IN BIOSCIENCE-LANDMARK (2021)

Add to Collection

Article Virology

Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test

Silvia Meschi et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce

F. Magro et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study

Related references

Export Citation

Share Paper